创投月报 | 金雨茂物：八个月六只基金合募超26亿 成长期项目投资占比超80%

Group 1 - The number of newly registered private equity and venture capital fund managers in August 2025 dropped to 5, a decrease of nearly 70% compared to July, and a 64.3% decline year-on-year [1] - A total of 368 new private equity and venture capital funds were registered, showing a year-on-year growth of 25.2%, but a slight month-on-month decrease of 1.9% [1] - The domestic primary equity investment market recorded 565 financing events, with a year-on-year increase of 28.4% and a month-on-month increase of 2.4%, while the total disclosed financing amount reached approximately 35.178 billion yuan, up 32.8% year-on-year [1] Group 2 - Jin Yu Mao Wu, established in 2004, has a fund management scale exceeding 16 billion yuan and has invested in over 300 companies, with more than 30 successfully listed [3] - The company focuses on strategic emerging industries such as new materials, intelligent manufacturing, new energy, and health care [3] - As of the end of August 2025, Jin Yu Mao Wu registered 6 funds with a total registered capital of 2.666 billion yuan [3] Group 3 - The Suzhou Jin Yu Intelligent Venture Capital Partnership, with a total scale of 1 billion yuan, focuses on early, growth, and mature stage companies in emerging and frontier equipment fields [4] - Jin Yu Mao Wu's investment activity has shown a "structural surge under a stable tone," with a significant increase in investment events in the second half of 2024 and early 2025 [4][6] - The company primarily invests in growth stage projects, with 83.3% of investments in A and B rounds [6] Group 4 - Jin Yu Mao Wu's investment strategy aligns with the trends of "high-end, intelligent, and green" industrial upgrades, focusing on advanced manufacturing and enterprise services [8] - The company has a strong local presence in Jiangsu, which is beneficial for leveraging local resources and capturing quality companies [10] - Investments are also made in regions like Beijing, Hubei, and Shenzhen to diversify risks and enhance collaborative effects [10] Group 5 - Commer Pharmaceutical, a one-stop CDMO enterprise, completed a financing round of several million yuan, with funds aimed at business development and R&D platform construction [12] - Jin Yu Mao Wu participated in Commer's A round financing in 2022, and the current investment is through a city-level industrial fund managed by Jin Yu Mao Wu [12]